Precision BioSciences, Inc. Email Format

Biotechnology ResearchNorth Carolina, United States51-200 Employees

Precision BioSciences, Inc. is a clinical-stage biotechnology company focused on in vivo gene editing via its ARCUS genome editing platform, which uses sequence-specific nucleases for gene knockout and enables more complex edits such as gene insertion or repair. Based in Durham, North Carolina, the company operates in the biotechnology research industry and employs between 51 and 200 people. It is developing gene editing therapies under programs including PBGENE-HBV and PBGENE-DMD, and has announced a licensing arrangement granting TG Therapeutics exclusive worldwide rights to develop and commercialize azer-cel in autoimmune diseases and other non-oncology indications. Precision BioSciences trades on Nasdaq under the ticker DTIL. The company has engaged in collaborations and industry events, such as a partnership with Terumo BCT and presentations of preclinical PBGENE-DMD data at the Muscular Dystrophy Association Clinical & Scientific Conference in 2026. These activities reflect ongoing development and the clinical-stage focus of the firm in the gene editing space.

Sign up for free to view info

Company overview Employee directory